rTMS Response & Remission Rates (Based on BDI-II)
The Transformative Impact of rTMS and Psychiatric Care on Treatment-Resistant MDD Patients
In the realm of psychiatric care, where traditional treatments may falter, innovative approaches offer new avenues of hope. Among these, Repetitive Transcranial Magnetic Stimulation (rTMS) has emerged as a promising intervention for individuals battling Treatment-Resistant Major Depressive Disorder (MDD). At Reconnect, a pioneering center for psychiatric care, the integration of rTMS with comprehensive treatment strategies has yielded remarkable outcomes, as evidenced by the substantial remission rates observed in our patient population.
At the one-month mark following the commencement of rTMS and psychiatric care at Reconnect, a remarkable 40% of patients experienced full remission from MDD (no longer meeting criteria for major depressive disorder) in addition to 60% of patients achieving at least a 50% reduction in their depression scores. This pivotal milestone, indicative of swift and tangible progress, signifies the efficacy of our integrated approach in alleviating symptom burden and fostering early signs of recovery.
Six months following the commencement of rTMS treatment combined with comprehensive psychiatric care at Reconnect, an astounding 66% of patients experienced full remission from MDD. Meaning that 66% of patients six months after receiving rTMS and psychiatric treatment at Reconnect no longer meet the criteria for depression (it is fully resolved). This remission rate comes from a treatment resistant population with individuals who have failed multiple medication trials and psychotherapies, representing a significant milestone in the journey towards mental wellness, underscores the effectiveness of our holistic approach in addressing the complexities of treatment-resistant depression.
